Literature DB >> 11472035

Early surgical intervention and strategy in patients with multiple endocrine neoplasia type 1.

P G Gauger1, N W Thompson.   

Abstract

Patients with multiple endocrine neoplasia type 1 (MEN-1) are an unusual challenge to the endocrine surgeon. Pituitary disease is often treated without surgery, but nearly all patients will require parathyroidectomy for parathyroid hyperplasia. Subtotal parathyroidectomy can be accomplished with a very low rate of permanent hypoparathyroidism and an acceptable rate of recurrent hyperparathyroidism. The treatment of pancreaticoduodenal disease is quite controversial. Even when associated with the Zollinger-Ellison syndrome, early and aggressive surgical treatment should be considered to influence the hormonal syndrome as well as to address the malignant potential of both pancreatic and duodenal tumours. This includes distal pancreatectomy, enucleation of pancreatic head lesions, and duodenotomy with the resection of gastrinomas. Many patients may be completely cured of the manifestations of their disease. As MEN-1 is an uncommon entity, there are very few prospective, randomized data upon which to base surgical judgements. Copyright 2001 Harcourt Publishers Ltd.

Entities:  

Mesh:

Year:  2001        PMID: 11472035     DOI: 10.1053/beem.2001.0136

Source DB:  PubMed          Journal:  Best Pract Res Clin Endocrinol Metab        ISSN: 1521-690X            Impact factor:   4.690


  10 in total

1.  Outcome of duodenopancreatic resections in patients with multiple endocrine neoplasia type 1.

Authors:  Detlef K Bartsch; Volker Fendrich; Peter Langer; Ilhan Celik; Peter H Kann; Matthias Rothmund
Journal:  Ann Surg       Date:  2005-12       Impact factor: 12.969

Review 2.  Inherited pancreatic endocrine tumor syndromes: advances in molecular pathogenesis, diagnosis, management, and controversies.

Authors:  Robert T Jensen; Marc J Berna; David B Bingham; Jeffrey A Norton
Journal:  Cancer       Date:  2008-10-01       Impact factor: 6.860

3.  Laparoscopic strategies for resection of insulinomas.

Authors:  Laureano Fernández-Cruz; Gleydson Cesar-Borges
Journal:  J Gastrointest Surg       Date:  2006-05       Impact factor: 3.452

4.  The surgical management of pancreaticoduodenal tumours in multiple endocrine neoplasia type 1.

Authors:  Sri G Thrumurthy; Ravindra S Date; Muntzer M Mughal; Kishore G Pursnani; Jeremy B Ward
Journal:  BMJ Case Rep       Date:  2009-04-14

Review 5.  The optimal surgical treatment for primary hyperparathyroidism in MEN1 patients: a systematic review.

Authors:  Jennifer M J Schreinemakers; Carolina R C Pieterman; Anouk Scholten; Menno R Vriens; Gerlof D Valk; Inne H M Borel Rinkes
Journal:  World J Surg       Date:  2011-09       Impact factor: 3.352

6.  Biochemically curative surgery for gastrinoma in multiple endocrine neoplasia type 1 patients.

Authors:  Masayuki Imamura; Izumi Komoto; Shuichi Ota; Takuya Hiratsuka; Shinji Kosugi; Ryuichiro Doi; Masaaki Awane; Naoya Inoue
Journal:  World J Gastroenterol       Date:  2011-03-14       Impact factor: 5.742

Review 7.  Resolved and unresolved controversies in the surgical management of patients with Zollinger-Ellison syndrome.

Authors:  Jeffrey A Norton; Robert T Jensen
Journal:  Ann Surg       Date:  2004-11       Impact factor: 12.969

8.  Laparoscopic surgery in patients with sporadic and multiple insulinomas associated with multiple endocrine neoplasia type 1.

Authors:  Laureano Fernández-Cruz; Isidro Martínez; Gleydson Cesar-Borges; Emiliano Astudillo; David Orduña; Irene Halperin; Gemma Sesmilo; Manuel Puig
Journal:  J Gastrointest Surg       Date:  2005-03       Impact factor: 3.452

Review 9.  Multiple Endocrine Neoplasia: Genetics and Clinical Management.

Authors:  Jeffrey A Norton; Geoffrey Krampitz; Robert T Jensen
Journal:  Surg Oncol Clin N Am       Date:  2015-07-27       Impact factor: 3.495

Review 10.  Surgical aspects of gastrinoma in multiple endocrine neoplasia type 1.

Authors:  Detlef K Bartsch; Peter Langer; Matthias Rothmund
Journal:  Wien Klin Wochenschr       Date:  2007       Impact factor: 2.275

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.